home / stock / algs / algs news

ALGS News and Press, Aligos Therapeutics Inc. From 12/08/22

Stock Information
Company Name: Aligos Therapeutics Inc.
Stock Symbol: ALGS
Market: NASDAQ
Website: aligos.com
Menu
ALGS ALGS Quote ALGS Short ALGS News ALGS Articles ALGS Message Board
Get ALGS Alerts

News, Short Squeeze, Breakout and More Instantly...
ALGS - Aligos Therapeutics Presents Nonclinical Data for its Coronavirus Therapeutic Program at the 2022 Respi DART Meeting

Coronavirus protease inhibitor, ALG-097558, has demonstrated antiviral activity in vivo and promising pan-coronavirus activity in vitro First-in-human studies anticipated to begin in H1 2023 SOUTH SAN FRANCISCO, Calif., Dec. 08, 2022 (GLOBE NEWSWIRE) -- Aligos Therapeutics, ...
ALGS - Aligos Therapeutics Presents Clinical Data for its NASH Program and Nonclinical Data for its Chronic Hepatitis B Portfolio at AASLD's The Liver Meeting® 2022

ALG-055009, a THR-β agonist drug candidate in development as a treatment for NASH, demonstrated dose-dependent reductions in several atherogenic lipids and a favorable pharmacokinetic profile in subjects with hyperlipidemia Aligos’ oral and poster presentations...

ALGS - Aligos Therapeutics Presents Clinical Data for its Capsid Assembly Modulator, ALG-000184, at AASLD's The Liver Meeting® 2022

SOUTH SAN FRANCISCO, Calif., Nov. 04, 2022 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases, will deliver a poster presentation at The ...

ALGS - Aligos Therapeutics GAAP EPS of -$0.44 beats by $0.14, revenue of $4.12M beats by $3.37M

Aligos Therapeutics press release ( NASDAQ: ALGS ): Q3 GAAP EPS of -$0.44 beats by $0.14 . Revenue of $4.12M beats by $3.37M . For further details see: Aligos Therapeutics GAAP EPS of -$0.44 beats by $0.14, revenue of $4.12M beats by $3.37M

ALGS - Aligos Therapeutics Reports Recent Business Progress and Third Quarter 2022 Financial Results

SOUTH SAN FRANCISCO, Calif., Nov. 02, 2022 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases, today reported recent business progress an...

ALGS - Aligos Therapeutics to Present Nonclinical and Clinical Data for its Chronic Hepatitis B and NASH Portfolio at AASLD's The Liver Meeting® 2022

SOUTH SAN FRANCISCO, Calif., Oct. 21, 2022 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases, today announced seven upcoming poster pres...

ALGS - Aligos Therapeutics to Announce Third Quarter Results November 2, 2022

SOUTH SAN FRANCISCO, Calif., Oct. 19, 2022 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, the “Company”), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases, today announc...
ALGS - Aligos Therapeutics to Present Data on pan-Coronavirus Protease Inhibitors for the Treatment of COVID-19 at Cambridge Healthtech Institute's 20th Annual Discovery on Target Conference, to be Held October 17-20, 2022 in Boston, MA

SOUTH SAN FRANCISCO, Calif., Oct. 18, 2022 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, the “Company”), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases, today announc...

ALGS - Aligos Therapeutics Initiates Dosing In Healthy Volunteers With siRNA Drug Candidate ALG-125755

Single ascending doses to be evaluated in healthy volunteers in Q4 2022 Single ascending doses to be evaluated in subjects with chronic hepatitis B beginning in Q1 2023 SOUTH SAN FRANCISCO, Calif., Oct. 14, 2022 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS),...

ALGS - Tracking Baker Brothers Portfolio - Q2 2022 Update

Summary Baker Brothers’ 13F portfolio value increased from $17.40B to $17.63B this quarter. Global Blood Therapeutics, Horizon Therapeutics, and Kymera Therapeutics were increased during the quarter. The top three positions are Seagen, Incyte Corporation, and BeiGene, a...
Previous 10 Next 10